Immuno-Oncology and Inflammation
HBM contact: Dr Matthias Fehr
Company status: private
Numab applies its proprietary antibody
discovery and engineering technology to generate highly potent and stable
antibody Fv fragments, which serve as building blocks to create mono- or
multispecific antibody fragment-based therapeutics with tailored pharmacokinetic
The company has created a broad proprietary pipeline of compounds in immune-oncology and the field of inflammation and has entered into several partnerships with pharmaceutical companies.